• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Sofinnova Partners S.A.S.

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. *

 

	Start	1997-08-25 established
	Group	Sofinnova (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997)
	Person 2	Lucquin, Denis (Sofinnova Partners 201509 Managing Partner + Chairman)
	Region	Paris
	Country	France
	Street	7–11 Boulevard Haussmann
	City	75009 Paris
	Tel	+33-1-7623-4100
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2020-04-22)
	Currency	EUR
	Annual sales	2,000,000,000 (funds, managed (2020) 2020-04-22)
		* Document for �About Section�: EnginZyme AB. (4/22/20). "Press Release: EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners". Stockholm.
		Record changed: 2021-04-05

Advertisement

More documents for Sofinnova (Group)

• [1] Sofinnova Partners. (3/3/21). "Press Release: Sofinnova Partners Closes €445M ($540M) Oversubscribed Late-stage Healthcare Crossover Fund". Paris....
• [2] Noema Pharma AG. (12/1/20). "Press Release: Noema Pharma Raises CHF54 Million in Series A Financing Round Led by Sofinnova Partners and Polaris Partners". Basel....
• [3] Catamaran Bio, Inc.. (11/23/20). "Press Release: Catamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors". Cambridge, MA....
• [4] Enthera S.r.l.. (7/28/20). "Press Release: Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease". Milan....
• [5] Sofinnova Partners. (6/10/20). "Press Release: Protera Closes $5.6M Series A Financing led by Sofinnova Partners". Santiago & Paris....
• [6] PinCell S.r.l.. (5/6/20). "Press Release: PinCell Appoints Veteran Biotech and Biopharma Executives to Management Team and Board of Directors. The Nominations Follow a Successful Seed Funding Led by Sofinnova Partners". Milan....
• [7] Genespire S.r.l.. (4/29/20). "Press Release: Genespire Secures €16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies. Biotech Executive, Julia Berretta, Ph.D., Is Named Chief Executive Officer". Milan....
• [8] EnginZyme AB. (4/22/20). "Press Release: EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners". Stockholm....
• [9] Sofinnova Partners. (4/20/20). "Press Release: Sofinnova Partners Announces Third Investment from its Italian Fund". Milan....
• [10] Jeito Capital. (1/15/20). "Press Release: Rafaèle Tordjman Launches Jeito Capital, a New Private Equity Company Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of Jeito I at €200 Million". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.